ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates for the treatment of both solid and hematological cancers. ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine based warheads to selectively kill cancer cells.

‍